Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2].

Ipragliflozin (L-Proline) selectively inhibits SGLT2 with IC50 of 2.8 nM.

PF-04971729 is a selective sodium-dependent glucose cotransporter (SGLT) inhibitor which selectively targets SGLT2.

Remogliflozin etabonate（GSK189075）是一种口服活性、选择性和低亲和力的钠-葡萄糖共转运蛋白（SGLT2）抑制剂，其对hSGLT2、rSGLT2、hSGLT1和rSGLT1的Ki值分别为1.95 μM、43.1 μM、2.14 μM和8.57 μM。

Dapagliflozin impurity是 Dapagliflozin 的对映异构体，Dapagliflozin是一种钠葡萄糖共转运蛋白 2 (SGLT2) 抑制剂。

Mizagliflozin是一种高效的 SGLT1 抑制剂，通过抑制小肠中的钠-葡萄糖共转运蛋白，改善餐后血糖水平，并有助于慢性便秘的治疗。它在糖尿病和胃肠道疾病的研究中具有应用前景。

KGA-2727是一种选择性高且口服活性的 SGLT1 抑制剂，具有显著的高亲和力。它对 SGLT1 的选择性远高于 SGLT2，并在抗糖尿病治疗中显示出显著效果。

Ipragliflozin is a selective inhibitor of SGLT2 with IC50 of 14 nM for hSGLT2.

LX4211 is an inhibitor of SGLT2 and SGLT1 with antidiabetic activity.

Trilobatin, a natural product isolated and purified from the herbs of Lithocarpus pachyphyllus with anti-oxidant effect, potentially inhibits the LPS-induced inflammatory response by suppressing the NF-κB signaling pathway and is a potential effective α-glucosidase inhibitor for management of postprandial hyperglycemia with less side effect.

Empagliflozin (BI 107730) 是一种选择性钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂，对人类SGLT-2的IC50为3.1 nM。

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) 是一种选择性的SGLT2抑制剂，在CHOK细胞中对mSGLT2、rSGLT2和hSGLT2的IC50值分别为2 nM、3.7 Nm和4.4 Nm。

Canagliflozin (JNJ 28431754)是一种选择性SGLT2抑制剂，其在CHOK细胞中对mSGLT2、rSGLT2和hSGLT2的IC50值分别为2 nM、3.7 nM和4.4 nM。

Phlorizin is an inhibitor of hSGLT1 (Ki=300 nM) and hSGLT2 (Ki= 39 nM). It can be found in a number of fruit trees.

Phloretin, a dihydrochalcone flavonoid, can inhibit the active transport of glucose into cells by SGLT1 and SGLT2. It is mainly found in fruit and roots of apple tree.

Tofogliflozin hydrate (CSG-452 hydrate)是一种高效、特异性和选择性的 SGLT2 抑制剂。IC50 值为 2.9 nM（人），14.9 nM（大鼠），6.4 nM（小鼠），部分抑制高糖诱导的肾小管细胞 ROS 生成。

Dapagliflozin（BMS-512148）是一种治疗糖尿病的新药，是一种竞争性钠/葡萄糖协同转运蛋白2（SGLT2）抑制剂，导致尿中葡萄糖排泄。Dapagliflozin诱导HIF1表达并减少肾缺血再灌注损伤。

Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor

Bexagliflozin is an inhibitor of SGLT2 with IC50 value of 2 nM.

O-Desethyl Dapagliflozin是一种 SGLT2 抑制剂